abstract |
Compounds of formula (I):wherein RA, RBare hydrogen, halogen, cyano, hydroxyl, alkyl, fluoroalkyl, fluoroalkoxy or alkoxy; R6is hydrogen, halogen, cyano, trifluoromethyl, carboxy or other substituents; R10is alkyl (including alkenyl), fluoroalkyl, cycloalkyl, optionally substituted phenyl or N-containing-heteroaryl, -alkyl-phenyl, - alkyl-(N-containing-heteroaryl), -alkyl-O-alkyl, alkoxy, -O-alkyl-phenyl, -NR16-alkyl or -NR16-alkyl-phenyl; R16is hydrogen or C1-4alkyl; R11is alkyl, haloalkyl, cycloalkyl, or optionally substituted benzyl; and pharmaceutically acceptable salts or N-oxides thereof may be useful as antagonists of Prostaglandin D2(PGD2) receptors. Also outlined are pharmaceutical compositions comprising the compounds of formula (I), and the use of these compounds in the treatment of respiratory, cardiovascular, inflammatory and other PGD2-dependent or PGD2-mediated conditions or diseases. Particular conditions include chronic obstructive disorder (COPD), asthma and allergic rhinitis. |